• Bristol Myers Squibb to acquire Forbius expresspharma
    August 26, 2020
    Forbius’s lead TGF-beta asset, AVID200, is an isoform-selective TGF-beta inhibitor, currently in Phase 1 for oncology and fibrosis.
PharmaSources Customer Service